Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker evaluation in HER2-positive metastatic breast cancer after prior anti-HER2 therapy
RBR-58ghgpPhase 2Recruiting
- Sponsor
- GSK
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lapatinib and trastuzumab in breast cancer (3 arms), sponsored by GSK. Started Jan 2016; status: recruiting.
02
Drugs
lapatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on RBR-58ghgp.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-58ghgp.